EU Approves Almirall’s Psoriasis Drug

Sun Pharma announced that Spanish drugmaker Almirall received European Commission approval for its psoriasis treatment Ilumetri (tildrakizumab).

The drug, which treats moderate-to-severe chronic plaque psoriasis in adults who are candidates for systemic therapy, modifies the pathogenesis of the disease without significant impact on the rest of the nervous system.

In July 2016, the Indian drug giant licensed the monoclonal antibody to Almirall for development and commercialization in Europe. The drug will be rolled out in Europe in the next few weeks.

Leave a Reply

Your email address will not be published. Required fields are marked *